Register for our webinar:
Lost in translation: how to use microphysiological systems to confidently progress to the clinic
26 September, 3pm UK time
The great divide between basic drug research and clinical outcomes is being ever-more scrutinized. As we reach greater technological heights in drug development, with new drug formats and biological agents becoming the new normal, the translational capabilities of traditional in vitro and in vivo models becomes ever more strained. The expression of human drug targets, enzymes, transporters and interacting proteins on appropriate tissues becomes crucial to the successful assessment of a drug candidate. Without them, candidates are likely to be incorrectly categorized, and either put forward at risk or wrongly removed from the pipeline in vitro.
Here, we present the use of the PhysioMimix OOC System in developing human and preclinical animal microphysiological systems to decrease the divide between in vitro, in vivo and the clinic in DILI risk assessments. These systems offer the ultimate translation tool to allow greater confidence in progressing candidates to successful clinical trials.
- Understand the current challenges in translation in drug development.
- Identify where MPS/OOC best fit within the drug discovery and development pipeline and how they are most suitably applied.
- Learn about the PhysioMimix human and preclinical animal liver MPS models and how they recapitulate the functionality of the liver.
- Determine how human and preclinical animal liver MPS are applied to predicting DILI risk
Dr. Emily Richardson
Lead Scientist - Toxicology, CN Bio Innovations
Read the bio
Dr Emily Richardson is a Lead Scientist in the Toxicology Assay Development team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix® lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics at Adaptimmune and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.
Alysha Bray
Scientist - Toxicology, CN Bio Innovations
Read the bio
Alysha Bray is a Scientist in the Toxicology Assay Development team at CN Bio. She joined the team in 2018 as a Research Assistant and has led and helped develop many of CN Bio’s MPS models. Alysha is highly experienced in cell biology and MPS model development. She completed her MSc in cell and gene therapy at University College London (UCL), looking into the epigenetic DNA modifications of lentiviral vectors. She now leads R&D projects within the CN Bio team revolving around toxicology using liver and other MPS organ models.
Register
Already registered? Click here to login.
CN Bio is committed to protecting and respecting your privacy. We will use your contact information to respond to your inquiry and thereafter, to keep you up to date with news, insights, and relevant content that may be of interest to you.
You can unsubscribe from these communications at any time. Please review our Privacy Policy for more detail.